Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring

Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring

Autor Cox, T. M. Google Scholar
Aerts, J. M. F. G. Google Scholar
Belmatoug, N. Google Scholar
Cappellini, M. D. Google Scholar
vom Dahl, S. Google Scholar
Goldblatt, J. Google Scholar
Grabowski, G. A. Google Scholar
Hollak, C. E. M. Google Scholar
Hwu, P. Google Scholar
Maas, M. Google Scholar
Martins, A. M. Autor UNIFESP Google Scholar
Mistry, P. K. Google Scholar
Pastores, G. M. Google Scholar
Tylki-Szymanska, A. Google Scholar
Yee, J. Google Scholar
Weinreb, N. Google Scholar
Instituição Univ Cambridge
Univ Amsterdam
Assistance Publ Hop Paris
IRCCS
St Franziskus Hosp
Univ WA
Cincinnati Childrens Hosp Med Ctr
Natl Taiwan Univ Hosp
Universidade Federal de São Paulo (UNIFESP)
Yale Univ
NYU
Childrens Mem Hlth Inst
Genzyme Corp
Univ Res Fdn Lysosomal Storage Dis
NW Oncol Hematol Associates PA
Resumo Enzyme replacement was introduced as treatment for non-neuronopathic Gaucher disease more than 15 years ago. To ensure the best use of this costly ultra-orphan agent, a systematic disease management approach has been proposed by an international panel; this includes the development, by consensus, of achievable treatment goals. Here we critically review these goals and monitoring guidelines and incorporate emerging experience of the disease in the therapeutic era, as well as contemporary clinical research. This review makes recommendations related specifically to the management of pregnancy; the appropriate use of splenectomy and bisphosphonate treatment; the relevance of biochemical markers to disease monitoring; and the use of semi-quantitative methods for assessing bone marrow infiltration. in addition, we identify key areas for development, including the requirement for a validated index of disease severity; the need to correlate widely used biomarkers with long-term disease outcomes, and the desirability of establishing agreed standards for monitoring of bone disease particularly in infants and children with Gaucher disease.
Idioma Inglês
Data 2008-06-01
Publicado em Journal of Inherited Metabolic Disease. Dordrecht: Springer, v. 31, n. 3, p. 319-336, 2008.
ISSN 0141-8955 (Sherpa/Romeo, fator de impacto)
Editor Springer
Extensão 319-336
Fonte http://dx.doi.org/10.1007/s10545-008-0779-z
Direito de acesso Acesso restrito
Tipo Resenha
Web of Science WOS:000256928700004
URI http://repositorio.unifesp.br/handle/11600/30691

Mostrar registro completo




Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)

Buscar DSpace


Navegar

Minha conta